Human papillomavirus E6 peptide–Human leukocyte antigen class I complex (HPV E6-HLA-I complex)

The Human papillomavirus (HPV) E6 peptide–Human leukocyte antigen (HLA) class I complex is a molecular assembly consisting of a short peptide fragment derived from the HPV E6 oncoprotein bound within the groove of an HLA class I molecule (NIH, JPT Peptide Technologies). This complex is presented on the surface of HPV-infected or transformed cells, serving as a critical target for the cellular immune system, particularly CD8+ cytotoxic T lymphocytes (Karger, NIH). In high-risk HPV types like HPV16 and HPV18, the E6 protein is constitutively expressed and plays a central role in oncogenesis by inducing the degradation of the tumor suppressor p53 (NIH). Because E6 is a foreign viral protein not expressed in healthy tissues, the E6-HLA complex represents a highly specific neoantigen-like target for cancer immunotherapy (ResearchGate, BMJ). Therapeutic strategies targeting this complex include T-cell receptor (TCR) engineered T-cell therapies, TCR-mimic antibodies, and therapeutic vaccines designed to elicit or enhance T-cell responses against these specific epitopes (NIH, Google Patents). Clinical challenges include the potential for tumor immune evasion through the downregulation of HLA molecules or the antigen processing machinery, as well as the need for precise HLA matching in patients (NIH).

Other names

HPV16 E6/HLA-A*02:01 complexHPV E6-MHC class I complexHPV16 E6(29-38)/HLA-A*02:01pMHC complex (HPV E6)HPV16 E6 peptide-HLA-A2 complex

Recognition of the specific viral peptide-HLA complex by engineered T-cell receptors (TCRs) or TCR-mimic antibodies, leading to targeted lysis of HPV-infected or transformed cells.